Skip to main content
SpringerLink
Log in

Brexpiprazole: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine D2 receptors, as well as a potent antagonist of 5-HT2A receptors and noradrenergic α1B and α2C receptors. In July 2015, brexpiprazole received its first approval in the USA for use as an adjunctive treatment of major depressive disorder (MDD) and the treatment of schizophrenia. In several countries, brexpiprazole is in development for MDDs, schizophrenia, post-traumatic stress disorder and agitation in patients with dementia of the Alzheimer’s type. This article summarizes the milestones in the development of brexpiprazole leading to its first global approval in MDD and schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.

    Article  PubMed  Google Scholar 

  2. Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351(3):585–95.

    Article  PubMed  Google Scholar 

  3. Otsuka Pharmaceutical Co. Ltd. Rexulti® (brexpiprazole) tablets for oral use: US prescribing information. 2015. http://www.otsuka-us.com. Accessed 6 Aug 2015.

  4. US Food and Drug Administration. FDA approves new drug to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder [media release]. 13 July 2015. http://www.fda.gov.

  5. Otsuka Pharmaceutical Co. Ltd. US FDA approves Otsuka and Lundbeck’s Rexulti® (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia [media release]. 10 July 2015. http://www.otsuka.co.jp.

  6. Otsuka Pharmaceutical Co. Ltd, H. Lundbeck A/S. Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S sign historic agreement to deliver innovative medicines with focus on psychiatric disorders worldwide [media release]. 10 Nov 2011. http://www.otsuka.co.jp.

  7. H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd. Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide [media release]. 11 Nov 2011. http://www.lundbeck.com.

  8. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–14.

    Article  PubMed  Google Scholar 

  9. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3):356–64.

    Article  CAS  PubMed  Google Scholar 

  10. Wong DF, Malikaarjun S, Raofinia A, et al. A phase I, open-label PET study of the pharmacokinetics, tolerability and D2/D3 striatal occupancy of single-dose oral OPC-34712 in healthy subjects [abstract no. 619]. Biol Psychiatry. 2011;69(9 Suppl 1):S187.

  11. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015. doi:10.4088/JCP.14m09688.

    Google Scholar 

  12. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015. doi:10.4088/JCP.14m09689.

    Google Scholar 

  13. Eriksson H, Weiller E, Weiss C, et al. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: meta-analysis of two pivotal studies [abstract no. 42]. In: American Psychiatric Association Annual Meeting. 2015.

  14. Thase M, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II, randomized, placebo-controlled study [abstract no. 193]. Neuropsychopharmacology. 2011;36:S302–4.

    Google Scholar 

  15. Menard F, Fava M, Davidsen CK, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study [abstract no. 174]. Biol Psychiatry. 2015;77(9 Supplement 1):S65.

  16. Davis LL, Ota A, Perry P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study [abstract no. 177]. Biol Psychiatry. 2015;77(9 Supplement 1):S66.

  17. Krystal A, Mittoux A, Meisels P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study [abstract no. 173]. Biol Psychiatry. 2015;77(9 Supplement 1):S64–5.

  18. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35.

    Article  PubMed  Google Scholar 

  19. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015. doi:10.1176/appi.ajp.2015.14101275.

    PubMed Central  Google Scholar 

  20. Skuban A, Correll CU, Kane JM, et al. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies [abstract no. 2089994]. Schizophr Bull. 2015;41:S333–4.

    Google Scholar 

  21. McQuade R, Hobart M, Forbes RA, et al. A phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (study 331-07-203) [abstract no. 140]. In: US Psychiatric and Mental Health Congress. 2011.

  22. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study [abstract no. 560]. Biol Psychiatry. 2015;77(9 Supplement 1):S203.

  23. Weiller E, Skuban A, Weiss C, et al. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies [abstract no. 57]. In: American Psychiatric Association Annual Meeting. 2015.

  24. Correll CU, Skuban A, Ouyang J, et al. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies [abstract no. 2089877]. Schizophr Bull. 2015;41:S307.

    Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sarah Greig is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Sarah L. Greig

Authors
  1. Sarah L. Greig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah L. Greig.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greig, S.L. Brexpiprazole: First Global Approval. Drugs 75, 1687–1697 (2015). https://doi.org/10.1007/s40265-015-0462-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0462-2

Keywords

Search

Navigation